Clinical Trial Update: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating depemokimab for hypereosinophilic syndrome is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Drugs mentioned

• Depemokimab (depemokimab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypereosinophilic Syndrome | Phase 3 | Status: RECRUITING